Global Formulation Development Outsourcing Industry to 2027


DUBLIN, April 12, 2022 /PRNewswire/ — The report “Formulation Development Outsourcing Market: Global Industry Trends, Share, Size, Growth, Opportunities and Forecast 2022-2027” has been added to from offer.

Research and Markets Logo

The global formulation development outsourcing market reached a value of US$21.1 billion in 2021. Looking ahead, the publisher expects the market to reach US$31.8 billion by 2027, posting a CAGR of 6.3% during the period 2022-2027. Keeping in mind the uncertainties of COVID-19, we continuously monitor and assess the direct and indirect influence of the pandemic on different end-use sectors. This information is included in the report as a major market contributor.

Formulation development refers to the process of determining the patentability, life cycle and success of the pharmaceutical product. It also involves pre-formulation, including development and characterization of analytical assays, screening of excipients to stabilize or improve product solubility, and dosage form development. It is often outsourced due to time pressure and lack of internal resources. Outsourcing formulation development also offers many benefits, such as compressing timelines, access to expertise, and providing additional insurance against product failures.

The growing prevalence of chronic diseases, such as diabetes, chronic obstructive pulmonary disease (COPD), cancer, asthma, arthritis and Alzheimer’s disease, is driving demand for new drug discovery and development . This, in turn, represents one of the key factors driving the outsourcing of formulation development services to Contract Research Organizations (CROs) around the world. On top of that, there is an increase in the need to overcome risk and save the time and money involved in moving the drug through the development pipeline.

As a result, leading pharmaceutical and biotech companies around the world are partnering with outsourcing services in the early stages of the drug development process. This, coupled with a significant increase in the need to innovate new drugs due to increasing patent expiration of major drugs, is contributing to the growth of the market. Additionally, increasing healthcare spending by commercial enterprises and government agencies in several countries is creating a favorable market outlook. Additionally, the coronavirus disease (COVID-19) outbreak has positively influenced the need for clinical trials to find an effective treatment for the contagious infection. This has resulted in large investments in research and development (R&D) to develop therapies, which is expected to drive the market.

Competitive Landscape:

The competitive landscape of the industry has also been reviewed along with the profiles of major players i.e. Aizant Drug Research Solutions Private Limited, Catalent Inc., Charles River Laboratories, Dr. Reddy’s Laboratories Ltd., Emergent BioSolutions Inc., Intertek Group plc, Irisys LLC (Recro Pharma), Laboratory Corporation of America Holdings, Lonza Group AG, Piramal Pharma Solutions, Quotient Sciences, Syngene International Limited (Biocon Limited) and Thermo Fisher Scientific Inc.

Answers to key questions in this report:

  • How has the global formulation development outsourcing market performed so far and how will it perform in the coming years?

  • What has been the impact of COVID-19 on the global formulation development outsourcing market?

  • What are the main regional markets?

  • What is the market breakdown by service?

  • What is the market breakdown by dosage form?

  • What is the market breakdown by application?

  • What is the market breakdown by end user?

  • What are the different stages of the industry value chain?

  • What are the key drivers and challenges in the industry?

  • What is the structure of the global formulation development outsourcing market and who are the key players?

  • How competitive is the industry?

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive Summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Global Formulation Development Outsourcing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakdown by Service
6.1 Preformulation Services
6.1.1 Market trends
6.1.2 Key segments Discovery and preclinical services Analytical services
6.1.3 Market Forecast
6.2 Optimization of formulations
6.2.1 Market trends
6.2.2 Key segments Phase I Phase II Phase III Phase IV
6.2.3 Market Forecast

7 Market Breakdown by Dosage Form
7.1 Injectables
7.1.1 Market trends
7.1.2 Market Forecast
7.2 Oral
7.2.1 Market trends
7.2.2 Market Forecast
7.3 Topical
7.3.1 Market trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market trends
7.4.2 Market Forecast

8 Market Breakdown by Application
8.1 Oncology
8.1.1 Market trends
8.1.2 Market Forecast
8.2 Genetic disorders
8.2.1 Market trends
8.2.2 Market Forecast
8.3 Neurology
8.3.1 Market trends
8.3.2 Market Forecast
8.4 Infectious Diseases
8.4.1 Market trends
8.4.2 Market Forecast
8.5 Respiratory
8.5.1 Market trends
8.5.2 Market Forecast
8.6 Cardiovascular
8.6.1 Market trends
8.6.2 Market Forecast
8.7 Others
8.7.1 Market trends
8.7.2 Market Forecast

9 Market Breakdown by End User
9.1 Pharmaceutical and biopharmaceutical companies
9.1.1 Market trends
9.1.2 Market Forecast
9.2 Government and academic institutes
9.2.1 Market trends
9.2.2 Market Forecast

10 Market Breakdown by Region

11 SWOT Analysis

12 Value chain analysis

13 Analysis of the five forces of carriers

14 Price Analysis

15 Competitive Landscape
15.1 Market structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Aizant Drug Research Solutions Private Limited Company Overview Product Portfolio
15.3.2 Catalent Inc. Presentation of the company Product portfolio Finance SWOT Analysis
15.3.3 Charles River Laboratories Company Overview Product portfolio Finance SWOT Analysis
15.3.4 Dr. Reddy’s Laboratories Ltd. Company overview Product Portfolio Finance SWOT Analysis
15.3.5 Emergent BioSolutions Inc. Company Overview Product portfolio Finance SWOT Analysis
15.3.6 Intertek Group plc Company Overview Product Portfolio Finance SWOT Analysis
15.3.7 Irisys LLC (RecroPharma) Company Overview Product portfolio
15.3.8 Laboratory Corporation of America Holdings Company Overview Product portfolio Finance SWOT Analysis
15.3.9 Lonza Group AG Company Overview Product portfolio Finance SWOT Analysis
15.3.10 Piramal pharmaceutical solutions Company Overview Product portfolio Finance
15.3.11 Quotient science Company Overview Product portfolio
15.3.12 Syngene International Limited (Biocon Limited) Company overview Product portfolio Finance
15.3.13 Thermo Fisher Scientific Inc. Company Overview Product portfolio Finance SWOT Analysis

For more information about this report visit

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716



View original content:—featuring-emergent-biosolutions-intertek-and-lonza-among-others – 301523696.html

SOURCE Research and Markets


Comments are closed.